Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Overview of attention for article published in Annals of Oncology, October 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 4 news outlets
blogs: 2 blogs
policy: 2 policy sources
twitter: 12 X users

patent: 1 patent
guideline: 8 clinical guideline sources
podcasts: 4 podcasts

Readers on

mendeley: 366 Mendeley

So far, Altmetric has seen 2 posts from 2 blogs.

Trial of Adjuvant Olaparib in BRCA1/2, EBC and High-risk Patients with Germline Pathogenic Variants: Overall Survival

Physician's Weekly, 01 Feb 2023

The following is the summary of “Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline…

Post-trial follow-up | Adjuvant Olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer.

SPECIALTIES, 17 Oct 2022

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and…

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity.